These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31286100)

  • 1. Posaconazole-Induced Hypertension Due to Inhibition of 11
    Thompson GR; Beck KR; Patt M; Kratschmar DV; Odermatt A
    J Endocr Soc; 2019 Jul; 3(7):1361-1366. PubMed ID: 31286100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals.
    Beck KR; Telisman L; van Koppen CJ; Thompson GR; Odermatt A
    J Steroid Biochem Mol Biol; 2020 May; 199():105605. PubMed ID: 31982514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid hypertension and hypokalaemia induced by posaconazole.
    Boughton C; Taylor D; Ghataore L; Taylor N; Whitelaw BC
    Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29472988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posaconazole-induced hypertension and hypokalemia due to inhibition of the 11β-hydroxylase enzyme.
    Barton K; Davis TK; Marshall B; Elward A; White NH
    Clin Kidney J; 2018 Oct; 11(5):691-693. PubMed ID: 30289132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole.
    Sanchez-Niño MD; Ortiz A
    Clin Kidney J; 2018 Oct; 11(5):688-690. PubMed ID: 30289131
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Thompson GR; Chang D; Wittenberg RR; McHardy I; Semrad A
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature.
    Adamidis A; Cantas-Orsdemir S; Tsirka A; Abbott MA; Visintainer P; Tonyushkina K
    Pediatr Endocrinol Rev; 2019 Mar; 16(3):335-358. PubMed ID: 30888125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posaconazole-Induced Pseudohyperaldosteronism.
    Kuriakose K; Nesbitt WJ; Greene M; Harris B
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal hypertension in children: 11beta-hydroxylase deficiency and apparent mineralocorticoid excess.
    Cerame BI; New MI
    J Pediatr Endocrinol Metab; 2000; 13(9):1537-47. PubMed ID: 11154148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
    Atanasov AG; Ignatova ID; Nashev LG; Dick B; Ferrari P; Frey FJ; Odermatt A
    J Am Soc Nephrol; 2007 Apr; 18(4):1262-70. PubMed ID: 17314322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular biology of 11β-hydroxylase and 11β-hydroxysteroid dehydrogenase enzymes.
    White PC; Pascoe L; Curnow KM; Tannin G; Rösler A
    J Steroid Biochem Mol Biol; 1992 Dec; 43(8):827-35. PubMed ID: 22217826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 11beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
    White PC
    Am J Med Sci; 2001 Dec; 322(6):308-15. PubMed ID: 11780688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state.
    Li A; Li KX; Marui S; Krozowski ZS; Batista MC; Whorwood CB; Arnhold IJ; Shackleton CH; Mendonca BB; Stewart PM
    J Hypertens; 1997 Dec; 15(12 Pt 1):1397-402. PubMed ID: 9431844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
    Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent mineralocorticoid excess.
    Funder JW
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):151-153. PubMed ID: 26956190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile hypertension, the role of genetically altered steroid metabolism.
    Ferrari P; Bianchetti M; Frey FJ
    Horm Res; 2001; 55(5):213-23. PubMed ID: 11740142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent mineralocorticoid excess syndrome: an overview.
    Palermo M; Quinkler M; Stewart PM
    Arq Bras Endocrinol Metabol; 2004 Oct; 48(5):687-96. PubMed ID: 15761540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation.
    Hoffmann WJ; McHardy I; Thompson GR
    Mycoses; 2018 May; 61(5):337-339. PubMed ID: 29385285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apparent mineralocorticoid excess.
    Benediktsson R; Edwards CR
    J Hum Hypertens; 1994 May; 8(5):371-5. PubMed ID: 8064785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
    Frey FJ; Odermatt A; Frey BM
    Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):451-8. PubMed ID: 15199296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.